



Serial no. 09/911,703

Attorney Docket no. 27693-01008

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Serial No.: **09/911,703**

Group Art Unit: **1644**

Confirmation No.: **4927**

Examiner: **R. Schwadron**

Filed: **25 July 2001**

Applicant: **Darrell R. ANDERSON et al.**

For: Therapeutic Application of Chimeric and Radiolabeled Antibodies to Human B Lymphocyte Restricted Differentiation Antigen for Treatment of B Cell Lymphoma

Box Sequence

Commissioner for Patents
U.S. Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

RESPONSE TO NOTICE TO COMPLY ... SEQUENCE DISCLOSURES

Sir:

This communication responds to the Notice regarding a *bona fide* nonresponsive amendment mailed 17 June 2004, setting a one month period for response. A petition to extend the period for response by four months, to and including 17 November 2004, accompanies this reply. Accordingly, this reply is timely filed.

The basis for the Notice was a noncompliant sequence listing under 37 C.F.R. § 1.821 *et seq.* A copy of the "Notice to Comply ..." supplied with the examiner's communication accompanies this response.

Please amend the application by substituting the attached paper-copy sequence listing for the sequence listing filed on 30 March 2004. The sequences in the new sequence listing are identical to the sequences in the application as filed. This amendment adds no new matter.

A computer-readable copy of the attached sequence listing is filed herewith on compact disc. In compliance with 37 C.F.R. § 1.821(e), the undersigned states that the paper and computer-readable copies of the sequence listing are identical.

Applicant believes that the application is in condition for examination on the merits and requests favorable and prompt action.

Respectfully submitted,



David L. Fitzgerald
Registration No. 47,347
Attorney for Applicant

SIDLEY AUSTIN BROWN & WOOD LLP
1501 K Street, N.W.
Washington, DC 2005
202-736-8818
17 November 2004